Luo Y, Yan Z, Chu X, Zhang Y, Qiu Y, Li H
Commun Biol. 2025; 8(1):221.
PMID: 39939814
PMC: 11821889.
DOI: 10.1038/s42003-025-07649-0.
Drakontaeidi A, Pontiki E
Pharmaceuticals (Basel). 2023; 16(12).
PMID: 38139766
PMC: 10746130.
DOI: 10.3390/ph16121639.
Schweipert M, Amurthavasan A, Meyer-Almes F
Explor Target Antitumor Ther. 2023; 4(3):447-459.
PMID: 37455831
PMC: 10344891.
DOI: 10.37349/etat.2023.00144.
Bonomi R, Girgenti M, Krystal J, Cosgrove K
Complex Psychiatry. 2022; 8(1-2):13-27.
PMID: 36545044
PMC: 9669946.
DOI: 10.1159/000524079.
Jansch N, Lang K, Meyer-Almes F
Int J Mol Sci. 2022; 23(19).
PMID: 36233076
PMC: 9569839.
DOI: 10.3390/ijms231911775.
Pathological Role of HDAC8: Cancer and Beyond.
Kim J, Cho H, Yoo J, Kim G, Jeon Y, Lee S
Cells. 2022; 11(19).
PMID: 36231123
PMC: 9563588.
DOI: 10.3390/cells11193161.
A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective Inhibitors.
Fontana A, Cursaro I, Carullo G, Gemma S, Butini S, Campiani G
Int J Mol Sci. 2022; 23(17).
PMID: 36077415
PMC: 9456347.
DOI: 10.3390/ijms231710014.
Design, Synthesis and Biological Characterization of Histone Deacetylase 8 (HDAC8) Proteolysis Targeting Chimeras (PROTACs) with Anti-Neuroblastoma Activity.
Darwish S, Ghazy E, Heimburg T, Herp D, Zeyen P, Salem-Altintas R
Int J Mol Sci. 2022; 23(14).
PMID: 35886887
PMC: 9322761.
DOI: 10.3390/ijms23147535.
Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention.
Ruzic D, Djokovic N, Srdic-Rajic T, Echeverria C, Nikolic K, Santibanez J
Pharmaceutics. 2022; 14(1).
PMID: 35057104
PMC: 8778744.
DOI: 10.3390/pharmaceutics14010209.
Histone Deacetylase Inhibitors: Providing New Insights and Therapeutic Avenues for Unlocking Human Birth.
Ilicic M, Zakar T, Gregson A, Hussein W, Smith R, Paul J
Reprod Sci. 2021; 29(11):3134-3146.
PMID: 34713433
DOI: 10.1007/s43032-021-00778-x.
Thiazolidinedione "Magic Bullets" Simultaneously Targeting PPARγ and HDACs: Design, Synthesis, and Investigations of their and Antitumor Effects.
Tilekar K, Hess J, Upadhyay N, Bianco A, Schweipert M, Laghezza A
J Med Chem. 2021; 64(10):6949-6971.
PMID: 34006099
PMC: 10926851.
DOI: 10.1021/acs.jmedchem.1c00491.
Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs).
Luo Y, Li H
Int J Mol Sci. 2020; 21(22).
PMID: 33266366
PMC: 7700698.
DOI: 10.3390/ijms21228828.
Discovery of novel potential selective HDAC8 inhibitors by combine ligand-based, structure-based virtual screening and in-vitro biological evaluation.
Debnath S, Debnath T, Bhaumik S, Majumdar S, Kalle A, Aparna V
Sci Rep. 2019; 9(1):17174.
PMID: 31748509
PMC: 6868012.
DOI: 10.1038/s41598-019-53376-y.
Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma.
Kassab S, Mowafy S, Alserw A, Seliem J, El-Naggar S, Omar N
J Enzyme Inhib Med Chem. 2019; 34(1):1062-1077.
PMID: 31072216
PMC: 6522981.
DOI: 10.1080/14756366.2019.1613987.
A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment.
Shen J, Najafi S, Stable S, Fabian J, Koeneke E, Kolbinger F
Cell Death Differ. 2018; 25(12):2053-2070.
PMID: 29515255
PMC: 6261943.
DOI: 10.1038/s41418-018-0080-0.
The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin A, Knoff J, Pflum M
Eur J Med Chem. 2017; 143:1790-1806.
PMID: 29150330
PMC: 5890937.
DOI: 10.1016/j.ejmech.2017.10.076.
HDAC8 regulates long-term hematopoietic stem-cell maintenance under stress by modulating p53 activity.
Hua W, Qi J, Cai Q, Carnahan E, Ayala Ramirez M, Li L
Blood. 2017; 130(24):2619-2630.
PMID: 29084772
PMC: 5731083.
DOI: 10.1182/blood-2017-03-771386.
HDAC6 Brain Mapping with [F]Bavarostat Enabled by a Ru-Mediated Deoxyfluorination.
Strebl M, Campbell A, Zhao W, Schroeder F, Riley M, Chindavong P
ACS Cent Sci. 2017; 3(9):1006-1014.
PMID: 28979942
PMC: 5620987.
DOI: 10.1021/acscentsci.7b00274.
Design, Synthesis, and Biological Evaluation of Tetrahydroisoquinoline-Based Histone Deacetylase 8 Selective Inhibitors.
Taha T, Aboukhatwa S, Knopp R, Ikegaki N, Abdelkarim H, Neerasa J
ACS Med Chem Lett. 2017; 8(8):824-829.
PMID: 28835796
PMC: 5554898.
DOI: 10.1021/acsmedchemlett.7b00126.
Structural Requirements of HDAC Inhibitors: SAHA Analogues Modified at the C2 Position Display HDAC6/8 Selectivity.
Negmeldin A, Padige G, Bieliauskas A, Pflum M
ACS Med Chem Lett. 2017; 8(3):281-286.
PMID: 28337317
PMC: 5346987.
DOI: 10.1021/acsmedchemlett.6b00124.